Trailing-twelve-month (TTM) revenue is $13.39 Million with a year-over-year growth of (64.15%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $889,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $864,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-12 |
| Q1 FY2026Period ended 2026-03-31 | $1,458,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-04 |
| Q2 FY2026Period ended 2026-06-30 | $10,181,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $13,392,000 |
Current P/S: $5,346,156,984 market capitalization ÷ $13,392,000 TTM revenue = 399.21x.
Market capitalization source: FMP quote. Quote observed 2026-10-02T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $10.18M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-02T20:00:32.315Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-01.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Collaboration Revenue | N/A | N/A | $436,000 | $370M | $35M | N/A |
| Collaborative Arrangement Material Rights | $47M | $47M |
$13.39M
$13.39 Million
(64.15%)
vs. $37.36M a year ago (TTM)
+37.32%
5 Year compound annual growth rate
1 Year
(64.15%)
3 Year
(57.13%)
5 Year
+37.32%
10 Year
+24.33%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $3.51M | ($31.49M) | (89.97%) |
| 2024 | $35.00M | ($335.00M) | (90.54%) |
| 2023 | $370.00M | +$369.56M | +84762.39% |
| 2022 | $436,000 | ($912.64M) | (99.95%) |
| 2021 | $913.08M | +$912.36M | +126893.18% |
| 2020 |
TTM Growth
(64.15%)
3-Year CAGR
(57.13%)
5-Year CAGR
+37.32%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 36 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-02T20:00:32.315Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-01.
| N/A |
| N/A |
| N/A |
| Collaborative Arrangement Material Rights Fourth Exclusive License | N/A | $7M | N/A | N/A | N/A | N/A |
|---|
| Duchenne Muscular Dystrophy License | $151M | $151M | N/A | N/A | N/A | N/A |
|---|
| Exclusive License | N/A | $900M | N/A | N/A | N/A | N/A |
|---|
| Grant | N/A | N/A | $762,000 | $1M | $2M | $4M |
|---|
| Myotonic Dystrophy Type One License | $51M | $51M | N/A | N/A | N/A | N/A |
|---|
| Myotonic Dystrophy Type One R And D Services | $1M | $1M | N/A | N/A | N/A | N/A |
|---|
| Specified Target Option Material Right | $12M | $12M | N/A | N/A | N/A | N/A |
|---|
| $719,000 |
| ($288.87M) |
| (99.75%) |
| 2019 | $289.59M | +$286.47M | +9169.85% |
| 2018 | $3.12M | ($37.87M) | (92.38%) |
| 2017 | $41.00M | +$35.83M | +693.90% |
| 2016 | $5.16M | +$4.92M | +1990.69% |
